[go: up one dir, main page]

WO1994005301A1 - Dermatitis treatment compositions containing sulphur, salicylic acid and dimethylsulphone - Google Patents

Dermatitis treatment compositions containing sulphur, salicylic acid and dimethylsulphone Download PDF

Info

Publication number
WO1994005301A1
WO1994005301A1 PCT/GB1993/001873 GB9301873W WO9405301A1 WO 1994005301 A1 WO1994005301 A1 WO 1994005301A1 GB 9301873 W GB9301873 W GB 9301873W WO 9405301 A1 WO9405301 A1 WO 9405301A1
Authority
WO
WIPO (PCT)
Prior art keywords
sulphur
salicylic acid
dermatitis
skin
methylsulphonylmethane
Prior art date
Application number
PCT/GB1993/001873
Other languages
French (fr)
Inventor
Aws Shakir Mustafa Salim
Original Assignee
Aws Shakir Mustafa Salim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aws Shakir Mustafa Salim filed Critical Aws Shakir Mustafa Salim
Priority to AU49744/93A priority Critical patent/AU4974493A/en
Publication of WO1994005301A1 publication Critical patent/WO1994005301A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof

Definitions

  • Housewife dermatitis is a very common condition which continues to raise considerable interest not only because of the complex mechanisms involved in its development, but also because of the therapeutic challenge it poses.
  • the condition represents the injury inflicted on the skin of the fingers and hands following contact with household detergents, cleansing agents and purifying substances.
  • the dermatitis manifests itself by dryness, roughening, thickening and fissuring of the fingers and hand. Exposure to sunlight for long periods, air pollutants and environmental irritants, promote the dermatitis and enhance its severity.
  • Housewife dermatitis remains a difficult condition to treat and it is, thus, the aim of the present invention to introduce an effective therapy which not only removes the dermatitis but also protects against its recurrence.
  • the mechanism responsible for the development of housewife dermatitis is complex. Although an extensive range of products is available on the market, none is designed to combat the factors behind the development of the dermatitis and none opposes the mediators of skin injury and damage which represent the final common pathway through which irritants such as detergents, produce their adverse skin effects.
  • the present invention aims, therefore, at directly addressing these issues by providing a synergistic composition which not only effectively treats housewife dermatitis and enhances its healing, but also protects against the recurrence of this condition. It follows that application of this invention to the skin improves its condition and maintains its texture and vitality.
  • the invention provides a synergistic composition suitable for use in the treatment of housewife dermatitis, which composition comprises precipitated sulphur with salicylic acid and methylsulphonylmethane.
  • the application of the composition to the skin of the hands has been found in a surprising and very unexpected manner to improve its condition in a number of ways including protection against irritation, maintenance of texture and vitality, and in particular the protection against and treatment of housewife dermatitis. It has also been noted that the composition has the advantageous property of adhesion to the skin thereby affording prolonged contact and enhanced therapeutic delivery. Moreover, the ingredients of the composition interact in a synergistic manner in that the sum of the action of all the ingredients used separately is less than that exhibited by the composition.
  • vasodilator such as menthol in order to further increase the effectiveness of the composition in the skin.
  • the present invention provides a composition of the invention in intimate admixture with a physiologically acceptable carrier, for use in improving the condition of the skin of the hands.
  • the present invention provides a topical formulation comprising a composition of the invention in intimate admixture with a pharmaceutically acceptable vehicle.
  • vehicle should be 'acceptable' in terms of being generally non-deleterious to the skin of the subject being treated and compatible with the other ingredients of the formulation. It will of course be appreciated that certain individuals have significantly more sensitive skins than the average and that in these special cases alternative vehicles to those normally used may need to be tried.
  • Suitable vehicles are well known in the art being noted for example in such standard works as the British Pharmacopoeia and the British National Formulary and include ointment bases and cream bases as well as lotions, pastes, jellies, sprays, aerosols and bath oils.
  • Ointments and creams may contain oleaginous absorption colloidal clays, thickening agents such as gum tragacanth or sodium alginate and other pharmaceutically acceptable accessory ingredients such as humectants, preservatives, buffers and antioxidants which have utility in such formulations.
  • Cream formulations are usually preferred as being most acceptable to the majority of users.
  • a particularly convenient base is one utilizing cetomacrogol, comprising for example 30% w/v cetomacrogol emulsifying ointment (30% w/v cetomacrogol emulsifying wax, 20% w/v liquid paraffin wax, 50% w/v white soft paraffin) in freshly boiled and cooled purified water with for example 0.1% w/v chlorocresol or 0.08% w/v propyl hydroxybenzoate, 0.15% w/v methyl hydroxybenzoate and, 1.5% w/v benzyl alcohol.
  • compositions of the present invention contain at least 0.5% w/w of each of the active ingredients preferably from 1 to 20% w/w, and most preferably from 2 to 10% w/w. These dosage levels do not, however, indicate that the relative ratios of the active ingredients should be identical.
  • compositions of the invention may be administered in a slow release or sustained release topical vehicle so that a prolonged therapeutic effect may be achieved.
  • the frequency of the topical application depends on the indication.
  • a liberal amount of the cream is gently rubbed for a few minutes into the skin of the hands 2 or 3 times a day. It is advisable to leave the evening application overnight to enhance the repair of the skin damage and to stimulate healing.
  • a once daily application suffices. Each application must be washed away with warm water before another one is used. Contact with the eyes and oral consumption must be avoided.
  • compositions should e prepared at a temperature of 25°C.
  • the powder form of the active ingredients is mixed well in a glass or stainless steel container and then the appropriate amount of cetomacrogol 'A' is added and mixed for 10 minutes. When menthol is being used, this should first be finely ground.
  • the composition is allowed to stand for one hour then placed in dark-coloured non-transparent glass containers and stored at temperatures not exceeding 26°C. After preparation the formulation should not be used for at least 12 hours and should not be left for too long exposed to the air or direct sunlight.
  • Example 1 The formulations illustrated in Example 1 may be used 1 to 3 times daily depending on whether the application is being administered for prophylactic or therapeutic reasons.
  • a once daily application is generally recommended.
  • a liberal amount of the cream is spread over the skin of the hands or the area to be treated, and gently rubbed in for a few minutes.
  • a second application is indicated and preferably used in the evening and left overnight.
  • a fresh application should not be used without having washed away the previous one, and this may be done using warm water alone. Treatment may be for a few days or weeks depending on each case and in particular the individual's existing skin condition and requirements.
  • Consecutive females who had been diagnosed to have housewife dermatitis (roughening, thickening and fissuring of the skin of the fingers and hands) were prospectively randomized (by drawing sealed envelopes) on a double blind basis, to treatment with various agents presented in a cetomacrogol 'A' base or with this base alone (control group) , to study the therapeutic effect of their twice daily application for four weeks, as shown in the Table below.
  • Ten females were allocated to each group and the overall age range for the study was 31 to 55 years. A successful therapeutic outcome was judged objectively by observing a complete healing of all the fissuring coupled with a return of the skin texture to its original smoothness.
  • Housewife dermatitis refers to thickening, roughening and fissuring of the skin of the fingers alone or with that of the main part of the hand. Twenty-six females (age range 32 to 55 years - mean 43) randomized to the control group and 24 females (age range 35 to 51 years - mean 42) randomized to the treatment group were fully evaluable. While no beneficial therapeutic effect occurred in the control group, this was realized in all the active therapy group cases (100%) . These women were observed to have acquired complete healing of their skin's fissures and a return of the skin's smoothness and originally normal texture and appearance.
  • the formulations were applied twice daily for ten days onto the shoulders and arms. Each application consisted of a liberal amount of the cream spread over the shoulders and arms then gently rubbed in for a few minutes. Three hours later, the application was washed away with warm water. Physical examination was carried out once every day during the ten days of study. Similarly, standard haematology and biochemistry tests (including liver and urinary function tests, blood glucose, serum amylase and blood gases) with urine examination were performed every day. An electrocardiogram with cardiac enzymes' level estimation were taken every other day. All the therapeutic doses were comfortably tolerated without any apparent allergic or adverse reactions. In addition, no toxicity was produced by any of these doses. It is, consequently, concluded that the formulations described under Example 1 are safe for clinical use in the recommended doses.
  • sulphur with salicylic acid and methylsulphonylmethane components are generally used in similar amounts, by weight, in the synergistic compositions of the invention, other ratios may also be used. Generally there is used a ratio of from 30:1 to 1:10, preferably from 15:1, most preferably from 3:1 to 1:1, by weight.
  • sulphur and salicylic acid may also be varied e.g. between 10:1 and 1:5, preferably 5:1 to 1:1, advantageously approximately

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to synergistic composition comprising sulphur with salicylic acid or a physiologically acceptable salt or ester thereof and methylsulphonylmethane and their use in formulations and methods of treatment and prophylaxis of housewife dermatitis and for protecting and improving skin condition.

Description

DERMATITIS TREATMENT COMPOSITIONS CONTAINING SULPHUR, SALICYLIC ACID AND DIMETHYLSULPHONE
Housewife dermatitis is a very common condition which continues to raise considerable interest not only because of the complex mechanisms involved in its development, but also because of the therapeutic challenge it poses. The condition represents the injury inflicted on the skin of the fingers and hands following contact with household detergents, cleansing agents and purifying substances. The dermatitis manifests itself by dryness, roughening, thickening and fissuring of the fingers and hand. Exposure to sunlight for long periods, air pollutants and environmental irritants, promote the dermatitis and enhance its severity.
Housewife dermatitis remains a difficult condition to treat and it is, thus, the aim of the present invention to introduce an effective therapy which not only removes the dermatitis but also protects against its recurrence.
The mechanism responsible for the development of housewife dermatitis is complex. Although an extensive range of products is available on the market, none is designed to combat the factors behind the development of the dermatitis and none opposes the mediators of skin injury and damage which represent the final common pathway through which irritants such as detergents, produce their adverse skin effects. The present invention aims, therefore, at directly addressing these issues by providing a synergistic composition which not only effectively treats housewife dermatitis and enhances its healing, but also protects against the recurrence of this condition. It follows that application of this invention to the skin improves its condition and maintains its texture and vitality.
The invention provides a synergistic composition suitable for use in the treatment of housewife dermatitis, which composition comprises precipitated sulphur with salicylic acid and methylsulphonylmethane.
In accordance with the present invention, the application of the composition to the skin of the hands has been found in a surprising and very unexpected manner to improve its condition in a number of ways including protection against irritation, maintenance of texture and vitality, and in particular the protection against and treatment of housewife dermatitis. It has also been noted that the composition has the advantageous property of adhesion to the skin thereby affording prolonged contact and enhanced therapeutic delivery. Moreover, the ingredients of the composition interact in a synergistic manner in that the sum of the action of all the ingredients used separately is less than that exhibited by the composition.
Advantageously, there is also included a vasodilator such as menthol in order to further increase the effectiveness of the composition in the skin.
In a further aspect, the present invention provides a composition of the invention in intimate admixture with a physiologically acceptable carrier, for use in improving the condition of the skin of the hands.
In another aspect, the present invention provides a topical formulation comprising a composition of the invention in intimate admixture with a pharmaceutically acceptable vehicle. The vehicle should be 'acceptable' in terms of being generally non-deleterious to the skin of the subject being treated and compatible with the other ingredients of the formulation. It will of course be appreciated that certain individuals have
Figure imgf000005_0001
significantly more sensitive skins than the average and that in these special cases alternative vehicles to those normally used may need to be tried.
Suitable vehicles are well known in the art being noted for example in such standard works as the British Pharmacopoeia and the British National Formulary and include ointment bases and cream bases as well as lotions, pastes, jellies, sprays, aerosols and bath oils. Ointments and creams may contain oleaginous absorption colloidal clays, thickening agents such as gum tragacanth or sodium alginate and other pharmaceutically acceptable accessory ingredients such as humectants, preservatives, buffers and antioxidants which have utility in such formulations.
Cream formulations are usually preferred as being most acceptable to the majority of users. A particularly convenient base is one utilizing cetomacrogol, comprising for example 30% w/v cetomacrogol emulsifying ointment (30% w/v cetomacrogol emulsifying wax, 20% w/v liquid paraffin wax, 50% w/v white soft paraffin) in freshly boiled and cooled purified water with for example 0.1% w/v chlorocresol or 0.08% w/v propyl hydroxybenzoate, 0.15% w/v methyl hydroxybenzoate and, 1.5% w/v benzyl alcohol.
In general, the compositions of the present invention contain at least 0.5% w/w of each of the active ingredients preferably from 1 to 20% w/w, and most preferably from 2 to 10% w/w. These dosage levels do not, however, indicate that the relative ratios of the active ingredients should be identical.
Advantageously, the compositions of the invention may be administered in a slow release or sustained release topical vehicle so that a prolonged therapeutic effect may be achieved.
The frequency of the topical application depends on the indication. When dermatitis is being treated, a liberal amount of the cream is gently rubbed for a few minutes into the skin of the hands 2 or 3 times a day. It is advisable to leave the evening application overnight to enhance the repair of the skin damage and to stimulate healing. For prophylaxis against housewife dermatitis, or for the maintenance of the vitality of the hands' skin and for the prevention of its dryness or roughening and fissuring, a once daily application, as stated above, suffices. Each application must be washed away with warm water before another one is used. Contact with the eyes and oral consumption must be avoided.
While not restricting the scope of the present invention, it is believed that the mechanism of action behind its beneficial effects involves to some degree scavenging the cytotoxic oxygen-derived free radicals which mediate tissue injury.
Further preferred features and advantages of the invention will be realised from the following Examples, which are presented by way of illustration only.
Example 1 - Preparation of cream for skin treatment
A. methylsulphonylmethane 5g precipitated sulphur 4g salicylic acid 2g cetomacrogol 'A' add to lOOg B. methylsulphonylmethane 5g precipitated sulphur 4g salicylic acid 2g menthol crystals lg cetomacrogol 'A' add to lOOg
These compositions should e prepared at a temperature of 25°C. The powder form of the active ingredients is mixed well in a glass or stainless steel container and then the appropriate amount of cetomacrogol 'A' is added and mixed for 10 minutes. When menthol is being used, this should first be finely ground. The composition is allowed to stand for one hour then placed in dark-coloured non-transparent glass containers and stored at temperatures not exceeding 26°C. After preparation the formulation should not be used for at least 12 hours and should not be left for too long exposed to the air or direct sunlight.
Example 2 - Use of topical cream
The formulations illustrated in Example 1 may be used 1 to 3 times daily depending on whether the application is being administered for prophylactic or therapeutic reasons. To protect the skin of the hands and fingers against the damage incurred by detergents and household agents, and to maintain its texture and prevent drying up, a once daily application is generally recommended. A liberal amount of the cream is spread over the skin of the hands or the area to be treated, and gently rubbed in for a few minutes. For therapeutic purposes, a second application is indicated and preferably used in the evening and left overnight. A fresh application should not be used without having washed away the previous one, and this may be done using warm water alone. Treatment may be for a few days or weeks depending on each case and in particular the individual's existing skin condition and requirements.
Example 3 - Detailed evaluation of the compositions and their active ingredients
Consecutive females who had been diagnosed to have housewife dermatitis (roughening, thickening and fissuring of the skin of the fingers and hands) , were prospectively randomized (by drawing sealed envelopes) on a double blind basis, to treatment with various agents presented in a cetomacrogol 'A' base or with this base alone (control group) , to study the therapeutic effect of their twice daily application for four weeks, as shown in the Table below. Ten females were allocated to each group and the overall age range for the study was 31 to 55 years. A successful therapeutic outcome was judged objectively by observing a complete healing of all the fissuring coupled with a return of the skin texture to its original smoothness.
Table : Effect of housewife dermatitis treatment
Treatment group (n = 10) successful therapy
cetomacrogol 'A'
sulphur 1% sulphur 2% sulphur 5% sulphur 10%
salicylic acid 1% salicylic acid 2% salicylic acid 5% salicylic acid 10%
sulphur 1% + salicylic acid 1% sulphur 2% + salicylic acid 2% sulphur 5% + salicylic acid 5% sulphur 10% + salicylic acid 10%
MSM 1% SM 2% SM 5% SM 10%
SM 1% -i- sulphur 1% + salicylic acid 1% SM 2% + sulphur 2% + salicylic acid 2% SM 5% + sulphur 5% + salicylic acid 5% SM 10% + sulphur 10% + salicylic acid 10%
Figure imgf000009_0001
SM : methylsulphonylmethane The results of this study clearly demonstrate that while neither sulphur nor salicylic acid exert any beneficial therapeutic effects against housewife dermatitis, their combination together affords some therapeutic gains. The addition, however, of methylsulphonylmethane synergistically intensifies these gains. Moreover, the results support the choice of the doses employed in Example 1 as being optimal.
Example 4 - Clinical trials
These trials were carried out in females on a prospective randomized (by drawing sealed envelopes) double blind basis to examine the effect of a particular treatment in comparison with that of its base (cetomacrogol 'A') alone (control group). The treatment code was only broken at the end of the trial period.
A. The therapeutic effect of the formulation described under Example l.B against housewife dermatitis when applied twice daily for 6 weeks was examined. Housewife dermatitis refers to thickening, roughening and fissuring of the skin of the fingers alone or with that of the main part of the hand. Twenty-six females (age range 32 to 55 years - mean 43) randomized to the control group and 24 females (age range 35 to 51 years - mean 42) randomized to the treatment group were fully evaluable. While no beneficial therapeutic effect occurred in the control group, this was realized in all the active therapy group cases (100%) . These women were observed to have acquired complete healing of their skin's fissures and a return of the skin's smoothness and originally normal texture and appearance.
No adverse effects or allergies were noticed in any case. B. The efficacy of the formulation described under example I.A in arrorαmg sy-npt-oinaπc rener, was examined in women who complained of itching and hyperaesthesia upon contact with detergents and other household chemicals but who had no obvious signs of dermatitis. The formulation or its base were applied onto the hands twice daily for ten days during the period of exposure. Twenty controls (age range 32 to 51 years - mean 40) and 21 treatment cases (age range 31 to
49 years - mean 38) were fully evaluable. Complete symptomatic relief was attained by all the active therapy cases (100%) , but in none of the controls. No adverse effects, allergies or hypersensitivities were incurred by the active treatment.
C. The prophylactic effect of the formulation described under Example l.B against the recurrence of housewife dermatitis, after it had been successfully treated, was investigated. All women were instructed to continue their routine housework as they did before they sought treatment for their dermatitis, and were instructed to apply their regimen as a hand cream, but leaving it overnight and washing it away in the morning with warm water. Treatment lasted for four months (end point of the study) . Twenty-five females (age range 28 to 54 years - mean 39) in the control group and 23 females (age range 31 to 51 years - mean 36) in the active therapy group were fully evaluable. Complete protection against the recurrence of housewife dermatitis with maintenance of the hands' smoothness and normal skin texture was observed in all members of the active therapy group (100%) , but in none of the controls.
Prolonged administration incurred no local or systemic adverse effects and was very well tolerated by all the cases studied. Example 5 - Toxicity studies
Groups of ten healthy male volunteers of an age range between 18 and 40 years were studied. The following formulations were prepared in a cetomacrogol 'A' base as generally detailed in Example 1:
1. methylsulphonylmethane 1% + sulphur 1% + salicylic acid 1%
2. methylsulphonylmethane 2% + sulphur 2% + salicylic acid 2%
3. methylsulphonylmethane 5% + sulphur 5% + salicylic acid 5%
4. methylsulphonylmethane 10% + sulphur 10% + salicylic acid 10%
5. methylsulphonylmethane 15% + sulphur 15% + salicylic acid 15%
The formulations were applied twice daily for ten days onto the shoulders and arms. Each application consisted of a liberal amount of the cream spread over the shoulders and arms then gently rubbed in for a few minutes. Three hours later, the application was washed away with warm water. Physical examination was carried out once every day during the ten days of study. Similarly, standard haematology and biochemistry tests (including liver and urinary function tests, blood glucose, serum amylase and blood gases) with urine examination were performed every day. An electrocardiogram with cardiac enzymes' level estimation were taken every other day. All the therapeutic doses were comfortably tolerated without any apparent allergic or adverse reactions. In addition, no toxicity was produced by any of these doses. It is, consequently, concluded that the formulations described under Example 1 are safe for clinical use in the recommended doses.
It will be appreciated that although the sulphur with salicylic acid and methylsulphonylmethane components are generally used in similar amounts, by weight, in the synergistic compositions of the invention, other ratios may also be used. Generally there is used a ratio of from 30:1 to 1:10, preferably from 15:1, most preferably from 3:1 to 1:1, by weight.
Furthermore the relative proportions of sulphur and salicylic acid may also be varied e.g. between 10:1 and 1:5, preferably 5:1 to 1:1, advantageously approximately
2:1.
For the avoidance of doubt it should be noted that the τ-erainology "housewife dermatitis" is not in any way intended to indicate a gender-specific condition or that use of the compositions and treatments of the invention is restricted to the female gender.

Claims

1. A synergistic composition, which composition comprises sulphur with salicylic acid or a physiologically acceptable salt or ester thereof and methylsulphonylmethane.
2. A composition according to claim 1 wherein said sulphur with salicylic acid or a physiologically acceptable salt or ester thereof and methylsulponylmethane are present in a ratio of from 15:1 to 1:5 by weight.
3. A composition according to claim 1 or claim 2 wherein said sulphur and salicylic acid are present in a ratio of from 10:1 to 1:5.
4. A composition according to any one of claims 1 to 3 wherein said sulphur is in the form of precipitated sulphur.
5. A composition comprising sulphur with salicylic acid or a physiologically acceptable salt or ester thereof and methylsulphonylmethane for use in the preparation of a formulation for the treatment and prophylaxis of housewife dermatitis.
6. A formulation comprising a composition according to any one of claims 1 to 4 in intimate admixture with a physiologically acceptable carrier therefor, for use in improving the condition of the skin.
7. A topical formulation according to claim 6 which contains at least 0.5% w/w of each of the sulphur with salicylic acid or a physiologically acceptable salt or ester thereof and the methylsulphonylmethane.
8. A formulation according to claim 7 which contains from 1 to 20% w/w of each of the sulphur with salicylic acid or a physiologically acceptable salt or ester thereof and the methylsulphonylmethane.
9. A method of prophylaxis or treatment of housewife dermatitis which comprises administering an effective dosage of a formulation according to claim 6.
10. A method of protecting and improving skin condition which comprises administering an effective dosage of a formulation according to claim 6.
11. A method according to claim 9 or claim 10 wherein is applied to the skin a topical formulation according to claim 7.
12. A method according to claim 11 wherein said topical formulation is applied to the skin at least 2 times per day.
PCT/GB1993/001873 1992-09-04 1993-09-03 Dermatitis treatment compositions containing sulphur, salicylic acid and dimethylsulphone WO1994005301A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU49744/93A AU4974493A (en) 1992-09-04 1993-09-03 Dermatitis treatment compositions containing sulphur, salicylic acid and dimethylsulphone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929218701A GB9218701D0 (en) 1992-09-04 1992-09-04 Housewife dermatitis treatment
GB9218701.2 1992-09-04

Publications (1)

Publication Number Publication Date
WO1994005301A1 true WO1994005301A1 (en) 1994-03-17

Family

ID=10721365

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/001873 WO1994005301A1 (en) 1992-09-04 1993-09-03 Dermatitis treatment compositions containing sulphur, salicylic acid and dimethylsulphone

Country Status (3)

Country Link
AU (1) AU4974493A (en)
GB (1) GB9218701D0 (en)
WO (1) WO1994005301A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105741A1 (en) * 2003-05-30 2004-12-09 Gianfranco De Paoli Ambrosi Cosmetic and/or pharmaceutical compositions comprising dimthylsulphone for the cure and prevention of irritation, inflammation and cutaneous erythema
RU2336867C2 (en) * 2003-05-30 2008-10-27 ПАОЛИ АМБРОЗИ Джанфранко ДЕ Composition for dermal application with photoprotective and antierythemal effect, containing sun filtre ant dimethylsulphone
EP2269615A1 (en) * 2003-05-30 2011-01-05 Gianfranco De Paoli Ambrosi Use of dimethyl sulphone in formulations for chemical peeling

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1012585A (en) * 1963-05-01 1965-12-08 Barnes Hind Lab Inc New compositions for use in acne and like conditions
GB2057263A (en) * 1979-08-30 1981-04-01 Herschler R J Compositions containing methylsulphonylmethane
JPS58198421A (en) * 1982-05-14 1983-11-18 Reiko Kosaka Composition for decoloring skin and treating skin disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1012585A (en) * 1963-05-01 1965-12-08 Barnes Hind Lab Inc New compositions for use in acne and like conditions
GB2057263A (en) * 1979-08-30 1981-04-01 Herschler R J Compositions containing methylsulphonylmethane
JPS58198421A (en) * 1982-05-14 1983-11-18 Reiko Kosaka Composition for decoloring skin and treating skin disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 8401, Derwent World Patents Index; Class B05, AN 84-002869 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105741A1 (en) * 2003-05-30 2004-12-09 Gianfranco De Paoli Ambrosi Cosmetic and/or pharmaceutical compositions comprising dimthylsulphone for the cure and prevention of irritation, inflammation and cutaneous erythema
JP2006525951A (en) * 2003-05-30 2006-11-16 デ・パオリ・アムブロスィ、ジアンフランコ Cosmetic and / or pharmaceutical composition for the treatment and prevention of irritation, inflammation and skin erythema
RU2336867C2 (en) * 2003-05-30 2008-10-27 ПАОЛИ АМБРОЗИ Джанфранко ДЕ Composition for dermal application with photoprotective and antierythemal effect, containing sun filtre ant dimethylsulphone
AU2003238687B2 (en) * 2003-05-30 2009-07-02 Gianfranco De Paoli Ambrosi Cosmetic and/or pharmaceutical compositions comprising dimthylsulphone for the cure and prevention of irritation, inflammation and cutaneous erythema
AU2003238687B8 (en) * 2003-05-30 2009-08-06 Gianfranco De Paoli Ambrosi Cosmetic and/or pharmaceutical compositions comprising dimthylsulphone for the cure and prevention of irritation, inflammation and cutaneous erythema
EP2269615A1 (en) * 2003-05-30 2011-01-05 Gianfranco De Paoli Ambrosi Use of dimethyl sulphone in formulations for chemical peeling

Also Published As

Publication number Publication date
AU4974493A (en) 1994-03-29
GB9218701D0 (en) 1992-10-21

Similar Documents

Publication Publication Date Title
EP0129003B2 (en) Cosmetic and dermatological compositions containing 1-alpha-hydroxycholecalciferol
US6048886A (en) Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
US6468564B1 (en) Topical compositions containing lotus for skin treatment
US5378461A (en) Composition for the topical treatment of skin damage
US9387227B2 (en) Method for treatment of sores and lesions of the skin
US5874094A (en) Cream formulation for topical application
US4585656A (en) Treatment of herpes
JPH08502074A (en) Tissue protection and regeneration composition
EP3713583B1 (en) Methods and compositions for treatment of skin
WO1994005250A1 (en) Synergistic compositions for hair restoration containing dimethylsulfone and a sulphydryl group releasing agent
USRE33107E (en) Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same
US5674539A (en) Method of treating skin and composition
US4945094A (en) Synergistic biologically active substances
CN109453083B (en) Moisturizing and allergy-relieving composition and application thereof
WO1994005293A1 (en) Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
WO1994005272A1 (en) Skin treatment compositions containing dimethylsulphone and dimethylsulphoxide
WO1994005301A1 (en) Dermatitis treatment compositions containing sulphur, salicylic acid and dimethylsulphone
GB2177917A (en) Dermatologically active substances
WO1994005302A1 (en) Dermatitis treatment compositions containing sulphur, salicylic acid and a sulphydryl group releasing agent
WO1994005279A1 (en) Dermatological treatment compositions containing dimethylsulphone and a sulfur containing amino acid
GB2221391A (en) Pharmaceutical compositions containing procaine
CN115671022A (en) Anti-aging microcapsule composition and preparation method and application thereof
JPH11505238A (en) Composition for treating skin symptoms
WO1994005291A1 (en) Skin cancer treatment compositions containing dimethyl sulphone and oxypurinol or allopurinol
CN113230154A (en) Composition with anti-allergy, relieving and anti-inflammation effects and preparation method and application thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA